Stone Capital and Biosyngen have partnered to establish a Biopharmaceutical Investment Fund in Singapore, the signing ceremony was held in Ascendas One Hub of Sino-Singapore Guangzhou Knowledge City.
Regeneron Pharmaceuticals has entered into a research collaboration and option licencing agreement with Vyriad to discover and develop new oncolytic (cancer-killing) virus-based treatments for various forms of cancer.
Cyclica, Inc. today announced a collaboration with Enamine Ltd., the world’s largest chemical supplier, to explore its huge readily accessible chemical space using Cyclica’s state-of-the-art AI-driven Ligand Design platform.
A2 Biotherapeutics, a biotechnology company developing innovative cell therapies for cancer patients, announced its official launch.
Boehringer Ingelheim and Eli Lilly and Company will modernise their current alliance as of 1 January 2020 and focus its combined expertise and investment on the continued development and commercialisation of Jardiance (empagliflozin) in type 2 diabetes, heart failure, and chronic kidney disease.
Amgen has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market.
Cycle Pharmaceuticals announced that it has signed an agreement with Catalent to develop innovative formulations targeting rare disease patients.
Pandion Therapeutics has signed a license and collaboration deal worth up to $795m with Japan-based Astellas Pharma to research, develop, and commercialise locally acting immunomodulators for autoimmune diseases of the pancreas.
Gilead Sciences and Glympse Bio announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical programme.
Takeda Pharmaceutical has signed a deal worth up to $420m with COUR Pharmaceutical Development to acquire an exclusive global license to develop and commercialise the latter’s CNP-101 (TAK-101).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.